476 related articles for article (PubMed ID: 34953513)
21. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
[TBL] [Abstract][Full Text] [Related]
22. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
23. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
24. Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine.
Sureshchandra S; Lewis SA; Doratt BM; Jankeel A; Coimbra Ibraim I; Messaoudi I
JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34935643
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.
Dalapati T; Williams CA; Giorgi EE; Hurst JH; Herbek S; Chen JL; Kosman C; Rotta AT; Turner NA; Pulido N; Aquino JN; Pfeiffer TS; Rodriguez J; Fouda GG; Permar SR; Kelly MS
Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38548700
[TBL] [Abstract][Full Text] [Related]
26. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Saxton M; Piantadosi A; Waggoner JJ; Douek DC; Rouphael N; Wrammert J; Suthar MS
Cell Rep Med; 2022 Feb; 3(2):100529. PubMed ID: 35233550
[TBL] [Abstract][Full Text] [Related]
27. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
29. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.
Brummelman J; Suárez-Hernández S; de Rond L; Bogaard-van Maurik M; Molenaar P; van Wijlen E; Oomen D; Beckers L; Rots NY; van Beek J; Nicolaie MA; van Els CACM; Boer MC; Kaaijk P; Buisman AM; de Wit J
Front Immunol; 2024; 15():1392477. PubMed ID: 38774878
[TBL] [Abstract][Full Text] [Related]
30. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
31. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
Payne RP; Longet S; Austin JA; Skelly DT; Dejnirattisai W; Adele S; Meardon N; Faustini S; Al-Taei S; Moore SC; Tipton T; Hering LM; Angyal A; Brown R; Nicols AR; Gillson N; Dobson SL; Amini A; Supasa P; Cross A; Bridges-Webb A; Reyes LS; Linder A; Sandhar G; Kilby JA; Tyerman JK; Altmann T; Hornsby H; Whitham R; Phillips E; Malone T; Hargreaves A; Shields A; Saei A; Foulkes S; Stafford L; Johnson S; Wootton DG; Conlon CP; Jeffery K; Matthews PC; Frater J; Deeks AS; Pollard AJ; Brown A; Rowland-Jones SL; Mongkolsapaya J; Barnes E; Hopkins S; Hall V; Dold C; Duncan CJA; Richter A; Carroll M; Screaton G; de Silva TI; Turtle L; Klenerman P; Dunachie S;
Cell; 2021 Nov; 184(23):5699-5714.e11. PubMed ID: 34735795
[TBL] [Abstract][Full Text] [Related]
33. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
[TBL] [Abstract][Full Text] [Related]
34. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.
Collier DA; Ferreira IATM; Kotagiri P; Datir RP; Lim EY; Touizer E; Meng B; Abdullahi A; ; Elmer A; Kingston N; Graves B; Le Gresley E; Caputo D; Bergamaschi L; Smith KGC; Bradley JR; Ceron-Gutierrez L; Cortes-Acevedo P; Barcenas-Morales G; Linterman MA; McCoy LE; Davis C; Thomson E; Lyons PA; McKinney E; Doffinger R; Wills M; Gupta RK
Nature; 2021 Aug; 596(7872):417-422. PubMed ID: 34192737
[TBL] [Abstract][Full Text] [Related]
35. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Sahin U; Muik A; Vogler I; Derhovanessian E; Kranz LM; Vormehr M; Quandt J; Bidmon N; Ulges A; Baum A; Pascal KE; Maurus D; Brachtendorf S; Lörks V; Sikorski J; Koch P; Hilker R; Becker D; Eller AK; Grützner J; Tonigold M; Boesler C; Rosenbaum C; Heesen L; Kühnle MC; Poran A; Dong JZ; Luxemburger U; Kemmer-Brück A; Langer D; Bexon M; Bolte S; Palanche T; Schultz A; Baumann S; Mahiny AJ; Boros G; Reinholz J; Szabó GT; Karikó K; Shi PY; Fontes-Garfias C; Perez JL; Cutler M; Cooper D; Kyratsous CA; Dormitzer PR; Jansen KU; Türeci Ö
Nature; 2021 Jul; 595(7868):572-577. PubMed ID: 34044428
[TBL] [Abstract][Full Text] [Related]
36. Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern.
Farkash I; Feferman T; Cohen-Saban N; Avraham Y; Morgenstern D; Mayuni G; Barth N; Lustig Y; Miller L; Shouval DS; Biber A; Kirgner I; Levin Y; Dahan R
Cell Rep; 2021 Dec; 37(11):110114. PubMed ID: 34883043
[TBL] [Abstract][Full Text] [Related]
37. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
Liu J; Budylowski P; Samson R; Griffin BD; Babuadze G; Rathod B; Colwill K; Abioye JA; Schwartz JA; Law R; Yip L; Ahn SK; Chau S; Naghibosadat M; Arita Y; Hu Q; Yue FY; Banerjee A; Hardy WR; Mossman K; Mubareka S; Kozak RA; Pollanen MS; Martin Orozco N; Gingras AC; Marcusson EG; Ostrowski MA
Sci Adv; 2022 Jan; 8(3):eabj9815. PubMed ID: 35044832
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.
Lozano-Ojalvo D; Camara C; Lopez-Granados E; Nozal P; Del Pino-Molina L; Bravo-Gallego LY; Paz-Artal E; Pion M; Correa-Rocha R; Ortiz A; Lopez-Hoyos M; Iribarren ME; Portoles J; Rojo-Portoles MP; Ojeda G; Cervera I; Gonzalez-Perez M; Bodega-Mayor I; Montes-Casado M; Portoles P; Perez-Olmeda M; Oteo J; Sanchez-Tarjuelo R; Pothula V; Schwarz M; Brahmachary M; Tan AT; Le Bert N; Berin C; Bertoletti A; Guccione E; Ochando J
Cell Rep; 2021 Aug; 36(8):109570. PubMed ID: 34390647
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
